rituximab的例句大全

Rituximab ( Rituxan sup > ) is a monoclonal antibody that is widely used for lymphoma.

利妥西单抗 ( 美罗华 ) 是广泛应用于淋巴瘤的单克隆抗体.

Conclusion: Treatment with lower dose rituximab may be an effective and safe approach in patient with ITP, However, the optimal therapeutic schedule, long-term efficacy, adverse events need to further investigation.

结论：小剂量美罗华是一种高效、安全治疗免疫性血小板减少症的药物，但其最佳用药方案、长期疗效以及不良反应仍有待于临床进一步明确。

Temozolomide United rituximab in the treatment of recurrent Central nervous system lymphoma ( a case report)

替莫唑胺联合美罗华治疗复发中枢神经系统淋巴瘤（附1例报告）

Patients get rituximab through infusion into a vein ( IV) at the oncologist's office or clinic.

患者可在肿瘤专家的办公室或门诊接受静脉注入美罗华。

Cell cycle alteration of Raji cells occurred in 131I-rituximab group, and the majority of cells were arrested at G1/ G2 stage.

131I-rituximab组Raji细胞周期发生变化，细胞大部分被阻滞于G1／G2期。

Nursing Care for Patients with B-Cell Non-Hodgkin's Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation Combined with Rituximab

2例B细胞非霍奇金淋巴瘤患者异基因造血干细胞移植联合利妥昔单抗治疗的护理

Systematic Review of Maintenance Rituximab Therapy in B Cell Non-Hodgkin Lymphoma

利妥昔单抗维持治疗B细胞非霍奇金淋巴瘤的系统评价

to observe the therapeutic effect and safety of rituximab ( anti-cd20 monoclonal antibody) in the treatment of refractory autoimmune hemolytic anemia ( aiha).

本研究初步观察抗CD20单克隆抗体利妥昔（rituximab）用于治疗难治性自身免疫性溶血性贫血（AIHA）的疗效和安全性。

preliminary study of new imaging agent,~ ( 99m) tc-rituximab, for sentinel lymph node biopsy of primary breast cancer

新型示踪剂~（99m）Tc-利妥昔用于原发性乳腺癌前哨淋巴结活检的初步研究

no long-term toxicity potentially due to rituximab was observed.

未见利妥昔单抗的长期潜在毒性。

rituximab in the treatment of blood diseases

利妥昔单抗在血液系统临床应用研究新进展

conclusion the use of rituximab treatment should be closely monitored to ensure the safety of drug use.

结论使用利妥昔单抗治疗应严密监护，保证用药安全。

treatment of b-cell lymphoma with the regimen of rituximab combined chemotherapy

利妥昔单抗联合化疗方案治疗B细胞淋巴瘤

clinical observation on rituximab combined with chemotherapy in the treatment of diffused large b cell lymphoma

利妥昔单抗联合化疗治疗弥漫型大B细胞淋巴瘤的临床观察

efficacy of rituximab in patients with refractory severe systemic lupus erythematosus

利妥昔单抗治疗难治性重症系统性红斑狼疮的临床初步观察

the rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin.

另外，相对于安慰机组，利妥昔单抗组的糖化血红蛋白和胰岛素必须量都明显较低。

the therapeutic effects of rituximab on 32 diffuse large b cell non-hodgkin lymphoma cases

美罗华治疗32例弥漫型大B细胞性非何杰金氏淋巴瘤

the clinical study of chop combined with rituximab in treating b-cell non-hodgkin lymphoma

美罗华联合CHOP治疗B细胞性非霍奇金淋巴瘤的临床研究

conclusion rituximab combined with chemotherapy is a highly effective and well-tolerated treatment in b cell nhl.

结论美罗华联合其它化疗药物治疗B细胞淋巴瘤疗效好，患者耐受好。

chop chemotherapy plus rituximab for elderly patients with diffuse large-b-cell lymphoma

CHOP方案联合利妥昔单抗治疗弥漫大B细胞淋巴瘤